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Abstract
Background: Tobacco smoking irritates and damages the respiratory tract and contributes to a higher risk of
developing lung emphysema. At present, smoking cessation is the only effective treatment for reducing the
progression of lung emphysema, however, there is hardly anything known about the effects of smoking cessation
on cytokine and chemokine levels in the airways. To the best of our knowledge, this is the first reported in vivo
study in which cytokine profiles were determined after cessation of cigarette smoke exposure.
Methods: The severity of airway remodeling and inflammation was studied by analyzing alveolar enlargement,
heart hypertrophy, inflammatory cells in the bronchoalveolar lavage fluid (BALF) and lung tissue and by
determining the cytokine and chemokine profiles in the BALF of A/J mice exposed to cigarette smoke for
20 weeks and 8 weeks after smoking cessation.
Results: The alveolar enlargement and right ventricle heart hypertrophy found in smoke-exposed mice remained
unchanged after smoking cessation. Although the neutrophilic inflammation in the BALF of cigarette smoke-
exposed animals was reduced after smoking cessation, a sustained inflammation in the lung tissue was observed.
The elevated cytokine (IL-1a and TNF-a) and chemokine (CCL2 and CCL3) levels in the BALF of smoke-exposed
mice returned to basal levels after smoking cessation, while the increased IL-12 levels did not return to its basal
level. The cigarette smoke-enhanced VEGF levels did not significantly change after smoking cessation. Moreover, IL-
10 levels were reduced in the BALF of smoke-exposed mice and these levels were still significantly decreased after
smoking cessation compared to the control animals.
Conclusion: The inflammatory changes in the airways caused by cigarette smoke exposure were only partially
reversed after smoking cessation. Although smoking cessation should be the first step in reducing the progression
of lung emphysema, additional medication could be provided to tackle the sustained airway inflammation.
Introduction
There are currently more than 1.3 billion tobacco smo-
kers worldwide according to the World Health Organi-
zation (WHO) [1]. Cigarette smoke contains more than
4000 hazardous chemical compounds, of which 200 are
highly toxic [2]. It is generally accepted that cigarette
smoking is the most important risk factor for the devel-
opment and progression of chronic obstructive pulmon-
ary disease (COPD) and accounts for about 80% of
COPD cases [3,4]. COPD, a term referring to two lung
diseases: chronic bronchitis and emphysema, is charac-
terized by an airflow limitation that is not fully reversi-
ble. The airflow limitation is usually both progressive
and associated with an abnormal inflammatory response
of the lungs to noxious particles or gases [5]. Pulmonary
hypertension and right ventricular failure are also often
associated with COPD [6,7]. Since a chronic airway
inflammation with alveolar wall destruction and airway
remodeling is central to the pathogenesis of COPD, it is
not surprising that several types of inflammatory cells
play a role in this condition [8]. Increased numbers of
macrophages and neutrophils are observed in sputum
a n db r o n c h o a l v e o l a rl a v a g ef l u i d( B A L F )o fC O P D
patients [9-11]. In addition, COPD patients have
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cells, in lung parenchyma and airways [11-14]. Migra-
tion and activation of inflammatory cells to the lung is
regulated by the release of different mediators, including
proteases, cytokines and chemokines secreted by a vari-
ety of inflammatory and resident cells. These mediators
contribute to the chronic inflammatory process with tis-
sue damage and repair processes seen in emphysema
[15,16]. Several cytokines and chemokines have been
implicated in the airway inflammation in COPD.
Increased levels of interleukin-8 (IL-8), interleukin-12
(IL-12), tumour-necrosis factor-a (TNF-a), monocyte
chemotactic protein-1 (MCP-1; CCL-2), and macro-
phage inflammatory protein-1a (MIP-1a;C C L 3 )h a v e
been observed in COPD patients [9,17-21]. In general,
the treatments available for COPD reduce the number
and severity of exacerbations and relieve symptoms, but
do not tackle the cause of the disease and have a lim-
ited effect on slowing down the progression of lung
damage [22]. At present, smoking cessation is the only
effective treatment for avoiding or reducing the progres-
sion of COPD [23]. However, there is contradictory evi-
dence regarding the effect of smoking cessation on
airway inflammation associated with COPD. Several stu-
dies in COPD patients reported that smoking cessation
improves respiratory symptoms, reduces loss of pul-
monary function and decreases lung inflammation
[24-28], while other studies have shown that smoking
cessation fails to reverse the chronic airway inflamma-
tion [29-32]. Unfortunately, there is insufficient evidence
regarding the effects of smoking cessation on cytokine
and chemokine levels, which do play an important role
in airway inflammation and tissue remodeling seen in
COPD. Therefore, a murine model of cigarette smoke-
induced lung emphysema was used to investigate the
effect of smoking cessation on airway remodeling and
pulmonary inflammation. The severity of airway remo-
deling and inflammation was studied by determining
alveolar enlargement, heart hypertrophy, inflammatory
cells in the bronchoalveolar lavage fluid (BALF)
and lung tissue and by analyzing the cytokine and che-
mokine profiles in the BALF of mice exposed to cigar-
ette smoke for 20 weeks and 8 weeks after smoking
cessation.
Materials and methods
Animals
Female A/J mice, 9-14 weeks old (Charles River Labora-
tories) were housed under controlled conditions in stan-
dard laboratory cages. They were provided free access to
water and food. All in vivo experimental protocols were
approved by the local Ethics Committee and were per-
formed under strict governmental and international
guidelines on animal experimentation.
Cigarette smoke exposure
Female A/J mice were divided into three groups. The
first group was exposed to room air for 20 weeks, the
second group was exposed to cigarette smoke for
20 weeks and the third group was exposed to cigarette
smoke for 20 weeks followed by a period of 8 weeks
without cigarette smoke exposure. 20-weeks-old mice
are adult mice and should have almost no alveolar
growth in the additional 8 weeks [33,34]. In the life-
span of a laboratory mouse 20 weeks smoking and
8 weeks smoking cessation represents approximately
21 years smoking and 8 years smoking cessation in
humans. The mice were exposed in whole-body cham-
bers to air (sham) or to diluted mainstream cigarette
smoke from the reference cigarettes 2R4F (University of
Kentucky, Lexington, Kentucky) using a smoking appa-
ratus. Exposures were conducted 4 h/day (with a 30/60-
minute fresh air break after each hour of exposure),
5 days/week for 20 weeks to a target cigarette smoke
concentration of 750 μg total particulate matter/l (TPM/
l). This TPM concentration was reached after an adapta-
tion period of 1 week, starting with a TPM concentra-
tion of 125 μg TPM/l. The mass concentration of
cigarette smoke TPM was determined by gravimetric
analysis of Cambridge filter samples. The carbon mon-
oxide (CO) was monitored continuously and was around
800 ppm. The nicotine concentration in the smoke was
approximately 40 μg/l. The sample sites were located in
the middle of the exposure chamber at the breathing
zone. The mice were sacrificed 16-24 hours after the
last air or smoke exposure, or after the smoke-free per-
iod of 8 weeks.
Histology and morphometric analysis
Mice (n = 4-5), used for morphometric analysis, were
sacrificed by an i.p. injection with an overdose of pento-
barbital (Nembutal™, Ceva Santé Animale, Naaldwijk,
The Netherlands). The lungs were fixated with a 10%
formalin infusion through the tracheal cannula at a con-
stant pressure of 25 cm H2O. After excision, the volume
of the fixed lungs was measured by fluid displacement.
Then, the left lung was immersed in fresh fixative for at
least 24 h, after which it was embedded in paraffin.
After paraffin embedding, 5 μm sections were cut and
stained with hematoxylin/eosin (H&E) according to
standard methods. These histological lung sections were
used to determine lung inflammation and pigmented
macrophages. Lung inflammation was scored by a treat-
ment-blind observer. The degree of peribronchial and
perivascular inflammation was evaluated on a subjective
scale of 0-3, as described elsewhere [35,36]. A value of 0
was assigned when no inflammation was detectable, a
value of 1 was adjudged for occasional cuffing with
inflammatory cells, a value of 2 when most bronchi or
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thick) of inflammatory cells, and a value of 3 was given
when most bronchi or vessels were surrounded by a
thick layer (more than five cells thick) of inflammatory
cells. Total lung inflammation was defined as the aver-
age of the peribronchial and perivascular inflammation
scores. Four lung sections per mouse were scored and
inflammation scores were expressed as a mean value.
Morphometric assessment of emphysema, included
determination of the average inter-alveolar distance, was
estimated by the mean linear intercept (Lm) analysis.
The Lm was determined by light microscopy at a total
magnification of 100×, whereby 24 random photomicro-
scopic images per left lung tissue section were evaluated
by microscopic projection onto a reference grid. By
dividing total grid length by the number of alveolar
wall-grid line intersections, the Lm (in μm) was calcu-
lated [37].
Bronchoalveolar lavage
Immediately after i.p. injection with an overdose of pen-
tobarbital, the lungs of a separate group mice (n = 4-5)
were lavaged 4 times through a tracheal cannula with 1
ml saline (NaCl 0.9%), pre-warmed at 37°C. The first
lavage was performed with 1 ml saline containing a mix-
ture of protease inhibitors (Complete Mini, Roche
Applied Science, Penzberg, Germany). After centrifuging
the bronchoalveolar lavage fluid at 4°C (400 g, 5 min),
the supernatant of the first ml was used for cytokine
analysis and the cell pellets of the 4 lavages were used
for cell counts. The 4 cell pellets, kept on ice, were
pooled per animal and resuspended in 150 μlc o l ds a l -
ine. After staining with Türk solution, total cell counts
per lung were made under light microscopy using
a Burker-Turk chamber. Differential cell counts were
performed on cytospin preparations stained by Diff-
Quick™(Dade A.G., Düdingen, Switzerland). Cells were
identified as macrophages, neutrophils and lymphocytes
according to standard morphology. At least 200 cells
were counted and the absolute number of each cell type
was calculated.
Right ventricular hypertrophy measurement
The right ventricle was removed from lower heart after
removal of the atria. The right ventricle and the left
ventricle plus septum were weighed and the ratio of the
weights was calculated as follows: (right ventricle)/(left
ventricle + septum) [38,39].
Measurement of cytokines and chemokines
A standard mouse cytokine 20-plex assay was used to
determine cytokine and chemokine concentrations in
the BALF (n = 4-5) according to the manufacturer’s
instructions (Luminex; Biosource, Invitrogen, Breda, The
Netherlands). The most relevant cytokines and chemo-
kines (IL-1a,I L - 1 0 ,I L - 1 2 ,T N F - a, CCL2, CCL3, VEGF
and macrophage inflammatory protein-2 (MIP-2;
CXCL2)) were discussed in this study. The concentra-
tions of these cytokines and chemokines were expressed
as pg/ml BALF.
Statistical analysis
Experimental results were expressed as mean ± S.E.M.
Differences between groups were statistically determined
by an unpaired two-tailed Student’s t-test using Graph-
Pad Prism (Version 4.0). Results were considered statis-
tically significant when P < 0.05.
Results
Alveolar enlargement induced by cigarette smoke
exposure is irreversible
The histological lung sections of the smoke-exposed
mice showed an increased air space enlargement and
destruction (Fig. 1B) compared with the air-exposed
mice (Fig. 1A). The alveolar enlargement is still present
after a smoking cessation period of 8 weeks (Fig. 1C).
The mean linear intercept, a quantification method for
alveolar size, was used to quantify the presence and
severity of emphysema [37]. Significant airspace enlarge-
ment was observed in mice after 20 weeks exposure to
cigarette smoke (Fig. 1D). Furthermore, airspace enlar-
gement induced by cigarette smoke exposure was not
reversible, since the increase in Lm was not significantly
reduced after a period of 8 weeks without exposure to
cigarette smoke (Fig. 1D).
Right ventricle heart hypertrophy related to cigarette
smoke exposure is irreversible
Twenty weeks cigarette smoke exposure caused right
ventricular heart hypertrophy (Fig. 2). The right ventri-
cular mass was proportionally greater than the rest of
the lower heart (left ventricle and septum) in smoke-
exposed mice compared to air-exposed mice. Moreover,
right ventricle heart hypertrophy was not reversible after
a period of 8 weeks without cigarette smoke exposure,
because the heart hypertrophy ratio (RV/LV +S) was not
significantly decreased in the smoking cessation group
compared to smoke-exposed group.
Lung volume increase after cigarette smoke exposure is
irreversible after smoking cessation
It has been demonstrated that chronic inflammation in
the airways ultimately leads to alveolar enlargement,
increased pulmonary compliance as well as enhanced
lung volumes [40]. We measured the lung volumes in
the murine lung emphysema model and the lung
volume was significantly increased in mice exposed to
cigarette smoke for 20 weeks compared to the control
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smoke exposure, the lung volume was still significantly
enhanced compared to the control group.
Smoking cessation reduces the inflammatory cell influx in
bronchoalveolar lavage fluid
Progression of COPD is associated with the accumula-
tion and activation of inflammatory cells in the BALF.
In the present lung emhysema model, the total number
of inflammatory cells was 5-fold increased in the BALF
after 20 weeks of cigarette smoke exposure (Table 1).
Differential cell counts demonstrated that most of the
cells in the BALF of the air-exposed mice were macro-
phages, with a few neutrophils and lymphocytes. The
number of all these inflammatory cells in the BALF was
significantly increased after cigarette smoke exposure,
especially the neutrophils. Cigarette smoke exposure
also affected the BALF cell composition, since there was
a shift observed from mainly macrophages in the control
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Figure 1 Cigarette smoke-induced alveolar enlargement is irreversible. Representative photomicrographs of hematoxylin and eosin stained
lung tissue of air-exposed mice (A), smoke-exposed mice (B), smoke-exposed mice 8 weeks after smoking cessation (C). Magnification, ×100.
Mean linear intercept (Lm) values of mice exposed to air (white bar), mice exposed to cigarette smoke for 20 weeks (black bar) and mice
exposed to cigarette smoke for 20 weeks plus a smoking cessation period of 8 weeks (grey bar) (D). n = 4-5 animals per group. Values are
expressed as mean +/- S.E.M. **P ≤ 0.01; significantly different from the control group.
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Figure 2 Cigarette smoke-induced right ventricle heart
hypertrophy is irreversible. Right ventricle (RV) and left ventricle
(LV) + septum (S) were dissected after 20 weeks air exposure (white
bar), after 20 weeks smoke exposure (black bar) and after 20 weeks
smoke exposure plus a smoking cessation period of 8 weeks (grey
bar) to determine their weight ratio (RV(LV+S)). n = 6-7 animals per
group. Values are expressed as mean +/- S.E.M. ***P ≤ 0.001;
significantly different from the control group.
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exposed mice. After smoking cessation of 8 weeks, we
found a significant decline in inflammatory cells in the
BALF, although the total cell number was still signifi-
cant different compared to the control group (Table 1).
First, the amount of neutrophils was strongly reduced
after smoking cessation, but these cell numbers were
still significantly increased compared to the control
mice. The macrophages were also decreased compared
to the smoke-exposed mice, however these numbers
were not returned to basal levels. Finally, the cigarette
smoke-induced increase of lymphocytes was not chan-
ged after cessation of cigarette smoke exposure. These
results indicate that smoking cessation leads to a reduc-
tion in inflammatory cell types and a change in cell
composition in the BALF, mainly caused by a decline in
neutrophils.
Lung inflammation is still present in lung tissue after
smoking cessation
Histological lung sections demonstrated that pulmonary
inflammation with peribronchial and perivascular
inflammatory cell infiltrates was present in the airways
of smoke-exposed mice (Fig. 4B). The air-exposed ani-
mals had no detectable lung inflammation (Fig. 4A).
The smoking cessation group showed that the peribron-
chial and perivascular airway inflammation was still pre-
sent after a smoke-free period of 8 weeks (Fig. 4C),
since there was no notable difference in the leukocyte
aggregates compared to those found in smoke-exposed
lungs. The scores of peribronchial, perivascular and total
lung inflammation were significantly increased after
20 weeks cigarette smoke exposure compared to air-
exposed mice and these scores were still significantly
enhanced after a smoking cessation period of 8 weeks
(Fig. 4D).
Moreover, there was an accumulation of brown-
pigmented macrophages in lung tissue of smoke-
exposed mice (Fig. 5B) compared to the lung tissue of
the control mice (Fig. 5A). These pigmented macro-
phages were still present after a smoking cessation per-
iod of 8 weeks (Fig. 5C).
The effect of smoking cessation on smoke-induced
changes in cytokine and chemokine levels in BALF
The levels of different cytokines and chemokines (IL-1a,
IL-10, IL-12, TNF-a, CCL2, CCL3 and VEGF) were
measured in the BALF of control mice and in smoke-
exposed mice before and after smoking cessation. Differ-
ences between the cytokine/chemokine profiles in the
BALF before and after smoking cessation were observed.
The concentrations of the pro-inflammatory cytokines
IL-1a and TNF-a were significantly elevated in the
BALF of the cigarette smoke-exposed mice compared to
the air-exposed mice (IL-1a: control: 0 pg/ml BALF ver-
sus smoke: 73.7 ± 8.7 pg/ml BALF, P < 0.001; TNF-a:
control: 17.1 ± 0.3 pg/ml BALF versus smoke: 33.1 ± 2.6
pg/ml BALF, P < 0.01). Both IL-1a and TNF-a returned
completely to basal levels after smoking cessation. The
cigarette smoke-enhanced IL-12 levels in the BALF did
not completely return to its basal level after smoking
cessation (Fig. 6A). In contrast to the pro-inflammatory
cytokines, the levels of the regulatory cytokine IL-10
were significantly decreased in the BALF after cigarette
smoke exposure. Although IL-10 levels were rising after
smoking cessation, the smoke-induced reduction was
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Figure 3 Lung volume increase after cigarette smoke exposure
is not reversible after smoking cessation. The relative lung
volume was measured by fluid displacement. The relative lung
volumes were determined after 20 weeks air exposure (white bar),
after 20 weeks smoke exposure (black bar) and after 20 weeks
smoke exposure plus a smoking cessation period of 8 weeks (grey
bar). n = 4-5 animals per group. Values are expressed as mean +/-
S.E.M. *P ≤ 0.05; significantly different from the control group.
Table 1 Immune cells in BALF recovered from air-exposed mice, smoke-exposed mice and smoke-exposed mice 8
weeks after smoking cessation
Control Smoke Smoke cessation
Total cell count, × 10
4 30.0 ± 3.2 140.4 ± 2.6 *** 52.8 ± 5.0 ** ^^^
Differential cell count, × 10
4
Macrophages 29.2 ± 3.1 56.1 ± 1.1 *** 42.4 ± 4.2 * ^
Neutrophils 0.27 ± 0.1 79.9 ± 3.5 *** 6.1 ± 0.5 *** ^^^
Lymphocytes 0.51 ± 0.1 4.4 ± 1.0 * 4.4 ± 1.0 *
n = 4-5 animals per group. Values are expressed as mean +/- S.E.M. *P ≤ 0.05, **P ≤ 0.01, ***P ≤ 0.001; significantly different from the control group. ^P ≤ 0.05,
^^^ P ≤ 0.001; significantly different from the smoke group.
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Figure 4 Lung inflammation is still present in lung tissue after smoking cessation. Representative photomicrographs of hematoxylin and
eosin stained lung tissue of air-exposed mice (A), smoke-exposed mice (B), smoke-exposed mice 8 weeks after smoking cessation (C).
Magnification, ×100. The histological sections were scored for the presence of peribronchial and perivascular inflammation (D). Total lung
inflammation was defined as the average of the peribronchial and perivascular inflammation scores. n = 4-5 animals per group. Values are
expressed as mean +/- S.E.M. ***P ≤ 0.001; significantly different from the control group.
ABC
Figure 5 Pigmented macrophage accumulation in the lung tissue before and after smoking cessation. Representative photomicrographs
of hematoxylin and eosin stained lung tissue of air-exposed mice (A), smoke-exposed mice (B), smoke-exposed mice 8 weeks after smoking
cessation (C). n = 4-5 animals per group. Magnification, ×400.
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(Fig. 6B). Furthermore, the chemokine levels CCL2 and
CCL3 were increased in the BALF of cigarette smoke-
exposed mice as compared to the control mice (CCL2:
control: 17.8 ± 0.2 pg/ml BALF versus smoke: 298.8 ±
47.7 pg/ml BALF, P < 0.01; CCL3: control: 12.1 ± 3.7
pg/ml BALF versus smoke: 133.6 ± 26.8 pg/ml BALF, P
< 0.01), while these chemokines returned completely
towards basal levels after smoking cessation. The VEGF
levels were enhanced in the BALF after chronic cigarette
smoke exposure and were still significantly elevated
compared to the air-exposed mice after 8 weeks smok-
ing cessation (Fig.6C).
Since no CXCL2 levels were detected in the BALF of
the smoke-exposed mice, CXCL2 levels were also exam-
ined in the lung homogenates of these animals. A signif-
icant increase of the CXCL2 concentration was observed
in the lung homogenates of the smoke-exposed mice
(4820.7 ± 820.1 pg/ml/mg protein, P < 0.05) compared
to the control animals (1108.1 ± 727.2 pg/ml/mg pro-
tein). After smoking cessation the smoke-induced
increase of CXCL2 levels was still evident (4175.6 ±
1338.6 pg/ml/mg protein).
Discussion
This study investigated the effects of smoking cessation
on airway remodeling and pulmonary inflammation.
First, airspace enlargement in the animal model for lung
emphysema was evident after 20 weeks cigarette smoke
exposure. This enlargement was not significant reduced
after smoking cessation, suggesting that induction of
lung emphysema by alveolar wall destruction is not
reversible. These findings are in agreement with the in
vivo data of Wright and Sun [41] and March et al. [42],
who demonstrated that emphysema was still present in
guinea pigs and mice after smoke exposure followed by
a smoking cessation period. Vernooy et al. [43] also
found that long-term LPS exposure results in irreversi-
ble alveolar enlargement in mice. The effect of cigarette
smoke is believed to be strain dependent. A/J mice were
used in the present COPD model, since this strain is
characterized as moderately susceptible to the develop-
ment of lung emphysema and to the lung inflammatory
response after acute cigarette smoke exposure [44,45].
The persistent emphysema observed in the present mur-
ine model is also similar to findings in people who have
stopped smoking. The alveolar enlargement and destruc-
tion seen in lung emphysema is generally thought to be
irreversible [46-48]. Besides the determination of lung
emphysema, we were interested in the lung volume. In
the current study, cigarette smoke-exposed mice showed
a significantly increased relative lung volume compared
to the air-exposed mice, which is a characteristic feature
of lung emphysema [40]. This lung volume was still sig-
nificantly enhanced after smoking cessation, which sup-
ported the irreversible alveolar changes after cigarette
smoke exposure.
Furthermore, right ventricle heart hypertrophy was
found in mice exposed to cigarette smoke, indicating
changes in the structure of the heart. Other authors also
demonstrated right ventricle heart hypertrophy as well
in animal models for lung emphysema as in COPD
patients [6,7,38,39,49]. A possible explanation for the
development of right ventricle heart hypertrophy could
be pulmonary hypertension, caused by hypoxic pulmon-
ary vasoconstriction or remodeling of the pulmonary
vessels, two important complications of COPD [6,50,51].
VEGF is identified as an endothelial cell specific growth
Figure 6 The effect of smoking cessation on smoke-induced changes in cytokine and chemokine levels in BALF. Levels of the pro-
inflammatory cytokine IL-12 (A), the regulatory cytokine IL-10 (B) and the growth factor VEGF (C) in the BALF of air-exposed mice (white bars),
smoke-exposed mice (black bars), smoke-exposed mice 8 weeks after smoking cessation (grey bars). n = 4-5 animals per group. Values are
expressed as mean +/- S.E.M. *P ≤ 0.05, **P ≤ 0.01, ***P ≤ 0.001; significantly different from the control group. ^P ≤ 0.05, ^^P ≤ 0.01;
significantly different from the smoke group.
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meability [52]. In the current study the increased VEGF
levels observed in the BALF of the smoke-exposed mice
could be involved in the pulmonary vascular remodeling
as a result of pulmonary hypertension, ultimately leading
to right ventricle heart hypertrophy. An enhanced
expression of VEGF was also observed in the pulmonary
vessels and arteries of COPD patients, suggesting an
important role for VEGF in the development of pulmon-
ary hypertension [53,54]. However, other studies suggest
that VEGF may have a protective role in the develop-
ment of pulmonary hypertension [55-57]. Like alveolar
enlargement, the right ventricle heart hypertrophy and
the increased VEGF in the BALF were irreversible after
smoking cessation. It is possible that the pulmonary
hypertension continued after the recovery period due to
the sustained lung damage and elevated VEGF levels,
which could lead to the ongoing heart hypertrophy. It
remains to be determined whether right ventricle heart
hypertrophy is directly related to lung emphysema or
whether other factors can play a role in the development
and maintaining of heart hypertrophy in COPD patients.
Airway inflammation was present in the airways of
mice exposed to cigarette smoke as shown by an
increase in total cell number in the BALF and by
inflammatory cell infiltration in the lung tissue. Analysis
of differential cell counts in BALF revealed a significant
increase in the number of macrophages, neutrophils and
lymphocytes in the smoke-exposed mice compared to
air-exposed mice, which is described in several in vivo
studies [58-61]. The histological lung sections and lung
inflammation scores of the smoke-exposed mice con-
firmed pulmonary inflammation with perivascular and
peribronchial cellular infiltrates, which has also been
demonstrated in other in vivo studies [62,63]. After
smoking cessation, the reduced numbers of inflamma-
tory cells in the BALF did not correlate with the sus-
tained inflammatory cell infiltration observed in lung
tissue. These results support the studies by Seagrave et
al. [64] and March et al. [42,64], who also observed air-
way inflammation and lower levels of inflammatory cells
in the BALF after smoking cessation. It should be noted
that it is very difficult to compare the numerous studies,
since the smoking cessation period, the duration of
smoking and the experimental set-up varied between
the studies, which could lead to discrepancies. Addition-
ally, several studies in COPD patients found a normal-
ized cell count in the BALF and sputum after smoking
cessation [24,25]. In contrast, other studies indicate that
there is an ongoing airway inflammation in COPD
patients who had stopped smoking [29-32]. These find-
ings indicate that inflammatory changes in the airways
of smoke-exposed mice are at least partially reversed
after smoking cessation. The persistent airway
inflammation (especially macrophages and lymphocytes)
could be related to the irreversible tissue damage in the
lungs, or to an ongoing microbial stimulus in the “sensi-
tive” airways of smokers [65-67] as discussed by Will-
emse et al. [31]. Another explanation could be that
COPD may have an autoimmune component that regu-
lates the sustained airway inflammation after smoking
cessation [68,69].
Little is known about cytokine and chemokine levels
in the BALF after smoking cessation. To the best of our
knowledge, this is the first reported in vivo study in
which cytokine profiles were determined after cessation
of cigarette smoke exposure. Increased levels of the pro-
inflammatory cytokines IL-1a,I L - 1 2a n dT N F - a were
observed in the BALF of cigarette smoke-exposed mice.
IL-1a and TNF-a levels returned to basal levels after
smoking cessation, while IL-12 was not normalized. The
cytokines IL-1a, IL-12 and TNF-a are mainly produced
by macrophages [70]. The alterations in these cytokine
levels are in line with the accumulated macrophage
levels before and reduced levels after smoking cessation.
As IL-12 is a potent Th1 skewing cytokine, we suggest a
Th1 polarization after cigarette smoke exposure. The
decreased IL-10 levels after smoke exposure will amplify
this polarization towards Th1, since IL-10 down-regu-
lates the expression of Th1 cytokines [71]. Other
authors also describe a possible association between
COPD and a Th1-driven immune response [72,73].
Moreover, after smoking cessation the IL-10 levels were
still significantly reduced compared to the air-exposed
animals. IL-10 could also play a role in function and dif-
ferentiation of the regulatory T cell, which is likely to be
associated with the control of immune responses in
COPD [74,75]. A significant increase of the CXCL2 con-
centration was observed in the lung homogenates of the
smoke-exposed mice compared to the control animals.
The CXCL2 increase is most probably important for the
neutrophil recruitment to the lungs following cigarette
smoke exposure, which is also indicated by Thatcher et
al. [63]. The chemokines CCL2 and CCL3 were also ele-
vated during COPD progression. This is in accordance
with the accumulated macrophage, neutrophil and lym-
phocyte levels in the BALF of the smoke-exposed mice,
since CCL2 is a monocyte chemoattractant and is pro-
duced by multiple cell types, including monocytes,
macrophages, endothelial cells and epithelial cells [76].
CCL3 is mainly released by monocytes/macrophages
and is involved in the recruitment and activation of pro-
inflammatory cells, such as T-cells, monocytes/macro-
phages and neutrophils [77,78]. Like IL-12, the synthesis
of CCL3 is typically associated with a Th1 milieu [79].
The CCL3 receptor, CCR1 is upregulated on Th1 cells
by IL-12 [80,81], while CCR5, is primarily expressed on
Th1 cells and promotes Th1 skewing [82,83]. Th1 cells
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T-cells. Since CCL3 attracts CD8+ lymphocytes, the ele-
vated CCL3 in the smoke-exposed mice could be related
to the increase in CD8+ T-cells seen in tissues of COPD
patients [84]. These Th1-related cytokines and chemo-
kines were markedly reduced after smoking cessation,
suggesting that the Th1 skewing will diminish after
smoking cessation.
Despite of the decrease in cell numbers and the reduc-
tion in cytokine and chemokine levels in the BALF after
smoking cessation, the current study demonstrated that
smoking cessation does not result in a profound reduc-
tion of airway inflammation, which is associated with
the sustained emphysema. First, the neutrophils in the
BALF were strongly reduced after smoking cessation to
almost basal levels, but were still significantly increased
compared to the control group. The macrophages in the
alveolar cavity were also not completely restored toward
basal levels after smoking cessation. Furthermore, the
cigarette smoke-induced increase of lymphocytes was
not changed after cessation of cigarette smoke exposure.
Finally, the histological lung sections showed that the
inflammatory cells and the brown-pigmented macro-
phages were still present in the lung tissue after smok-
ing cessation of 8 weeks, confirming the results
described by Seagrave et al. [64]. The pigmented macro-
phage has been a consistently reported inflammatory
cell type in COPD and contains characteristic brown-
pigmented cytoplasmic inclusions believed to be by-pro-
ducts of cigarette smoke [85-87]. It could be that these
brown-pigmented macrophages together with the ele-
vated lymphocytes in the BALF are responsible for the
sustained airway inflammation observed in the lung tis-
sue after smoking cessation. Future research is needed
to investigate whether this ongoing inflammation is per-
manent after smoking cessation.
In conclusion, cigarette smoke exposure leads to irre-
versible lung damage and heart hypertrophy. The
inflammatory changes in the airways caused by cigarette
smoke exposure were only partially reversed after smok-
ing cessation. Although smoking cessation should be the
first step in reducing the progression of lung emphy-
sema, additional medication could be provided to tackle
the sustained airway inflammation.
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